Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.

In this executive summary, learn the important details to consider when selecting a clinical supply partner in early phase studies that can have longer term implications during late phase.

As pharma companies look more and more to biologics for their next potential blockbusters, they must face the challenges surrounding these products' scientific complexity and sophisticated development.

This article explores the biologics landscape, market insights and trends, and provides future projections for what the global biologics market, including cell and gene therapy, will look like over the coming years.

This executive summary discusses imperative that companies invest adequate time and resources in strategic planning and preparation activities to ensure the best chances for a successful commercial launch.

Summary: Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound...

How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?